Navigation Links
Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets
Date:11/8/2010

ST LOUIS, Nov. 8, 2010 /PRNewswire-FirstCall/ -- Solutia Inc. (NYSE: SOA) announced today that it has sold its Perkalink® business and entered into a definitive agreement to sell select Primary Accelerators assets to LANXESS, a Germany-based specialty chemicals company.      

(Logo: http://photos.prnewswire.com/prnh/20081029/AQW096LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081029/AQW096LOGO)

"The sale of the Perkalink business is yet another strategic step forward in focusing Solutia's Flexsys® portfolio on the manufacture and supply of high-value, global market-leading rubber chemicals," said Greta Senn, president and general manager of Solutia's Technical Specialties division.  "In addition, our ability to sell select assets of Solutia's discontinued Primary Accelerators business allows us to maximize the value of those assets as we exit the business."

Solutia's Technical Specialties division offers advanced chemical and specialty products that meet or exceed rigorous specifications and are distributed through a reliable, global supply system. As one of the world's largest producers of chemicals for the rubber and tire industry, Flexsys products help control the process of manufacturing rubber, while improving its durability, flexibility and appearance.  The Perkalink business represented less than 1% of Solutia's consolidated sales in 2009.  For more information on Solutia and its diverse portfolio of product solutions, please visit www.solutia.com .

Notes to Editor:  Solutia, Flexsys and the Infinity Logo® and all other trademarks listed below are trademarks of Solutia Inc. and/or its affiliates.

Forward Looking Statements

This press release may contain forward-looking statements, which can be identified by the use of words such as "believes," "expects," "may," "will," "intends," "plans," "estimates" or "anticipates," or other comparable terminology, or by discussions of strategy, plans or intentions.  These statements are based on management's current expectations and assumptions about the industries in which Solutia operates.  Forward-looking statements are not guarantees of future performance and are subject to significant risks and uncertainties that may cause actual results or achievements to be materially different from the future results or achievements expressed or implied by the forward-looking statements.  These risks and uncertainties include, but are not limited to, those risk and uncertainties described in Solutia's most recent Annual Report on Form 10-K, including under "Cautionary Statement About Forward Looking Statements" and "Risk Factors", and Solutia's quarterly reports on Form 10-Q.  These reports can be accessed through the "Investors" section of Solutia's website at www.solutia.com.  Solutia disclaims any intent or obligation to update or revise any forward-looking statements in response to new information, unforeseen events, changed circumstances or any other occurrence.

Corporate Profile

Solutia is a market-leading performance materials and specialty chemicals company. The company focuses on providing solutions for a better life through a range of products, including: Saflex® polyvinyl butyral interlayers for glass lamination and for photovoltaic module encapsulation and VISTASOLAR® ethylene vinyl acetate films for photovoltaic module encapsulation;  LLumar®, Vista™, EnerLogic™, FormulaOne®, Gila®, V-KOOL®, Huper Optik®, IQue™, Sun-X® and Nanolux® aftermarket performance films for automotive and architectural applications; Flexvue™ advanced film component solutions for solar and electronic technologies; and technical specialties products including Crystex® insoluble sulfur, Santoflex® PPD antidegradants, Therminol® heat transfer fluids and Skydrol® aviation hydraulic fluids. Solutia's businesses are world leaders in each of their market segments. With its headquarters in St. Louis, Missouri, USA, the company operates globally with approximately 3,400 employees in more than 50 worldwide locations. More information is available at www.Solutia.com .


'/>"/>
SOURCE Solutia Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Solutia Opens New Photovoltaic Laboratory
2. Solutia to Present at Credit Suisse Future Energy Conference
3. Solutia Reports Third Quarter 2009 Results
4. Solutia Reports First Quarter 2009 Results
5. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
6. TPC Group Announces Commencement of Dutch Auction Tender Offer to Repurchase for Cash up to $130 Million in Common Stock
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Hoya Announces Second Quarter Financial Results
9. Metamark Genetics, Inc. Announces New Chief Executive Officer
10. Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
11. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , ... May 24, 2016 , ... Last week, Callan ... corporate executives and entrepreneurs, held The Future of San Diego Life Science event at ... Diego life science community attended the event with speakers Dr. Rich Heyman, former CEO ...
(Date:5/23/2016)... 23, 2016 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2016. The cash dividend of $0.24 ... 2016 to stockholders of record as of the close of ... subject to approval of the Board of Directors and may ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... interest organization focused on molecular nanotechnology, announced the winners for the 2015 Foresight ... physicist Richard Feynman, are given in two categories, one for experiment and the ...
(Date:5/20/2016)... ... 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural ... to treat the disease. Surviving Mesothelioma has just posted an article on the new ... institutions based their mesothelioma study on the fact the Manumycin A, a derivative of ...
Breaking Biology Technology:
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... http://www.apimages.com ) - --> - Renvoi : ... - --> --> ... solutions biométriques, fournit de nouveaux lecteurs d,empreintes digitales ... LF10 de DERMALOG sera utilisé pour produire des ...
(Date:3/9/2016)... , March 9, 2016 This BCC Research ... states of the RNA Sequencing (RNA Seq) market for ... as instruments, tools and reagents, data analysis, and services. ... segments of the RNA-Sequencing market such as RNA-Sequencing tools ... the main factors affecting each segment and forecast their ...
Breaking Biology News(10 mins):